Read our New Year message (https://compasspathways.com/to-our-community/)



About us Our research Our team Join us News & Views Investors Responsibility Contact (https://compasspathways.com/contact/)

**COMPASS** news

(https://compasspathways.com/category/articles/compassnews/) January 04, 2022

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology



# Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist suppor

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in psilocybin on cognitive and emotional functions in healthy participants: results from a phase I, randomised, placebo-controlled trial involving simultaneous psilo



The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg), compared with placebo, in 89 healthy male and female adult volunteer: therapists throughout the session, which lasted about six hours. The study involved a 12 week follow-up period. There were no serious adverse events and COM



Dr James Rucker, the study's lead author from King's IoPPN and honorary consultant psychiatrist at South London and Maudsley NHS Foundation Trust, said: "Ti giving it to more than one person at the same time, so we can think about how we scale the treatment up. This therapy has promise for people living with severe Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways, said: "This study was an early part of our clinical development programme for COMP360 psilocyb



label study of patients taking SSRI antidepressants alongside psilocybin therapy. We are looking forward to meeting with the FDA early in the year to finalise pla

<sup>1</sup>The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving sir Mistry, Francesco Saldarini, Susan Stansfield, Sara J Tai, Sam Williams, Neil Weston, Ekaterina Malievskaia, and Allan H Young) was published in the Journal of Ps

#### About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental hea COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Admi conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three week of the conduction of the cond $York and San Francisco in the US. Our vision is a world of mental wellbeing. \underline{www.compasspathways.com} (\underline{http://www.compasspathways.com})$ 

### Availability of other information about COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing unc

#### Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, for or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements contain these words. phase III programme and the potential for that or other trials to support regulatory filings and approvals, COMPASS's ability to continue to advance its research nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, an

These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our pre-(SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC's website at www.sec.gov. Except as required current expectations and speak only as of the date hereof.

## About King's College London and the Institute of Psychiatry, Psychology & Neuroscience

King's College London (https://eur03.safelinks.protection.outlook.com/?

 $\underline{url=https\%3A\%2F\%2Fwww.kcl.ac.uk\%2F\&data=04\%7C01\%7Cserena.rianjongdee\%40kcl.ac.uk\%7C112675f70fa640cdbb3b08d92a75dd79\%7C8370cf1416f3cff.$ is one of the top 35 UK universities in the world and one of the top 10 in Europe (QS World University Rankings, 2020/21) and among the oldest in England. Kir (loPPN) at King's is the premier centre for mental health and related neurosciences research in Europe. It produces more highly cited outputs (top 1% citations) prevent and treat mental illness and other conditions that affect the brain

www.kcl.ac.uk/ioppn (https://eur03.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.kcl.ac.uk%2Fioppn&data=01%7C01%7Cioppn-pr%40kcl.ac.uk

Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024 Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324 About us Our research Our team Join us News & Views Investors Responsibility

Contact (https://compasspathways.com/contact/)

Home (https://compasspathways.com) - COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

Useful links

Contact us Clinical trials

(https://compasspathways.com/contact/\(\)(https://compasspathways.com/our-research/psilocybin-

therapy/clinical-trials/)

About psilocybin therapy, About us (https://compasspathways.com/our-(https://compasspathways.com/about-research/psilocybin-therapy/about- us/)

psilocybin-therapy/)

Sign up to receive the latest COMPASS news & views.

(https://compasspathways.com/contact)

<u>Subscribe</u>

Join us News & Views (https://compasspathways.com/join-(https://compasspathways.com/news-us/) views/).

Annual Review 2020 (https://compasspathways.com/annual-review-2020/)

Unsolicited Information Policy (https://compasspathways.com/unsolicited-information-policy/) Terms (https://compasspathways.com/terms/) Privacy (https://compasspathways.com/privacy/) COMPASS © 2022. All rights reserved.

Follow us